China Pharma Hldgs Inc (NYSEMKT:CPHI)

Tracking portfolio for China based companies that gained listings on US exchanges (Nasdaq, NYSE, or Amex) after conducting reverse mergers. Stocks that have been delisted have been omitted. Start date: Jun 24, average P/E of these companies: 3.

I've learned a little trick these Chinese companies are using. Have you noticed they all have China in their name? How many companies do you know that have America, Canada, Germany, etc... in their names? The reason they put China in their name is to draw in foreign investors, because China means growth. Most of these companies are frauds and you should stay away from them.

This is a tracking portfolio of all CAPS-ratable tickers in the Chinese RTO/SPAC space (i.e., companies that listed without filing an IPO).

China Pharma Holdings, Inc. went public via a reverse merger in 2005. The company is based in China.

Solid company, just need to stop diluting shareholders.

3Y EPS>10%/yr, P/E < 20, insider interest, P/B < 20

Real healthcare products in China. Cash flows are good.
Max PE ~14
Min PE ~5

Low P/E, good growth, low PEG

At current P/E, with these fundamentals, sitting comfortable in the fastest growing economy in the world, backed here by the top Fools on this board... seems like a no brainer to me.

Bulishbao chose this, and he's the top leader so....

solid company, short term sell off has made this a great buying opportunity

CPHI is worth at least $4.

Tremendous growth prospects, solid history

Very efficient and great growth/value. This stock, even after the price increase, still looks attractive.

A big run up in price BUT with Rev and Earns Growth up 53% an 39% respectively and a 7.6 P/E how can you ignore it?

Unbelievable fundamentals.. Current P/e 7.5, forward p/e 6.31
PEG: .44
Price/sales: 2.75
Price/book: 1.86
Profit Margin: 35%
Revenue growth: 25%
mmmm...chinese medicine

Chinese pharmaceuticals! Little debt, great fundamentals.

Generic high occurance drug/medical manufacturer in China with low visibility and strong financials. This could be a nice long term multibagger.

undervalued

CHINA GROWTH